Sino Biopharmaceutical Limited's high P/S ratio may not be j...

Sino Biopharmaceutical Limited's high P/S ratio may not be justified due to its slower revenue growth. Investors may hope for a business turnaround, but analysts lack confidence. The weak revenue outlook could risk the share price and shareholder investments.